Medicine
Enflonsia 105 mg/0.7 mL injection
Enflonsia 105 mg/0.7 mL injection is a prescription medicine containing Clesrovimab for intramuscular use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store prefilled syringes under refrigeration at 36°F to 46°F (2°C to 8°C)…
Key facts
- Active ingredient (INN)
- Clesrovimab
- Brand
- Enflonsia
- Strength
- 105 mg/0.7 mL
- Dosage form
- Injection
- Route
- Intramuscular
- Packs
- 1 syringe of 0.7 mL, 10 syringes of 0.7 mL
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store prefilled syringes under refrigeration at 36°F to 46°F (2°C to 8°C). After removal from the refrigerator, ENFLONSIA must be used within 48 hours or discarded. Do not freeze. ENFLONSIA may be kept at room temperature between 68°F to 77°F (20°C to 25°C) for a maximum of 48 hours. Keep the prefilled syringe in the original carton to protect from light until time of use. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J06BD10 Clesrovimab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 June 2025
- Identifiers
- DailyMed set ID c9004a92-40e8-4cdb-b22d-d07929f8fc3bNDC 0006-5073Application BLA761432
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / .7 mL in 1 syringe, glass | 0006-5073-01 | Merck Sharp & Dohme | 9 June 2025 |
| 10 syringe, glass in 1 carton / .7 mL in 1 syringe, glass | 0006-5073-02 | Merck Sharp & Dohme | 9 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Clesrovimab is a respiratory syncytial virus anti-F protein monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. MedsAcross supplies Clesrovimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ClesrovimabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ENFLONSIA prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Enflonsia: European public assessment report (EPAR) · European Medicines Agency
Need Enflonsia 105 mg/0.7 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.